| abstract |
The present invention relates to a quinazoline derivative of formula (I) or a salt thereof, a process for their preparation, and a pharmaceutical composition comprising as an active ingredient a compound of formula (I) or a pharmaceutically acceptable salt thereof.n n n Formula In n n n n n n n In the above formula,n n n m is an integer of 1 to 3,n n n R 1 represents halogeno or (C 1 -C 3 ) alkyl,n n n X 1 represents -O-,n n n R 2 is three groups listed below, namelyn n n (1) (C 1 -C 5 ) alkylR 3 , wherein R 3 is hydroxy, halogeno, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) hydroxyalkyl and (C 1 -C 4 ) piperidin-4-yl, which may contain one or two substituents selected from alkoxy),n n n (2) (C 2 -C 5 ) alkenylR 3 , wherein R 3 is as defined above, andn n n (3) (C 2 -C 5 ) alkynylR 3 , wherein R 3 is as defined aboven n n Is selected fromn n n Wherein any alkyl group, alkenyl group or alkynyl group may contain one or more substituents selected from hydroxy, halogeno and amino.n n n The compound of formula (I) or a pharmaceutically acceptable salt thereof inhibits the action of VEGF as a property effective in treating a number of disease states including cancer and rheumatoid arthritis. |